Member Info for Brighty1

Some TOM info for newbies. 12 months ago TOM had high hopes of developing a plant but they had minimal cash. That all changed earlier this year. TOM raised cash and now is a stronger and much less risky company in October 2020 than it was at 6p last year. TOM has 100% investments in 9 shale leases, of over 15,488 acres in Utah. In addition - and this is what excites many investors here - 10,000 bopd compares to approx $430,000 a day. i.e. they could be generating returns equal to the entire current mcap of TOM every 9-10 days. Proactive Investors ran an excellent research article on this a few months ago. This is why at some stage TOM will be hitting the 8-10p range. When it happens that is a x 10 / x 15 multi bag from today. Good luck, Brighty.

https://www.proactiveinvestors.co.uk/companies/news/922129/tomco-energy-analyst-highlights-attractive-economics-of-a-new-oil-sands-separation-technology-922129.html

It went to 6.2p in July 2019. All the pieces of the jigsaw are slotting in to place one by one. Good luck, Brighty

Hopefully the stock market will be informed soon on Nigel's "Collaborations" and the possible transformational in vivo studies demonstrating the capability of Nuvec in generating Covid-19 specific antibodies. You only have to look at what has happened with the share prices of Novacyt, Synairgen, Avacta, Omega, Yourgene, Hemogenyx, Physiomics, Sareum, ValiRx in the last few months to realise how very big this could be. Good luck, Brighty

It is certainly worth flagging up again to remind investors of the magnitude of the contract opportunity for Omega via Abingdon /the consortia. i.e. 25% ££££ to ODX. Good luck, Brighty

The 217p broker target is good to see Proselenes. Thanks David for posting on FB. Lexion your calculations look well thought through. I'm with you on the spring £2 share price. My only fear, as I have said a few times on here, is a low ball takeover by a major before we achieve the 200p+ share price that we all so believe in. Good luck, Brighty

This was x 10 the current share price last July (19th July 2019 = 6.2p) & that was based purely on speculation. It was also above 2p intraday earlier this year. i.e. possible big gains to come in my opinion. Also, agree on the marketing point made by Torreaguas. If this is PR'd correctly moving forward in support of news this will have a huge re-rate. The key point now is that there is real news to come as opposed to speculation. Good luck, Brighty.

Some 2 million buys being reported this morning. Interesting management update also.

02-Nov-20 08:23:05 0.60 2,000,000 Buy* 0.55 0.60 12.00k O
02-Nov-20 08:22:03 0.595 2,000,000 Buy* 0.50 0.60 11.90k O
02-Nov-20 08:19:16 0.54999 1,500,000 Buy* 0.50 0.55 8,250 O

Good luck, Brighty

The real trick for Sareum in the next few days and weeks is going to be for Citigate, for once, to achieve a mention or two in similar national articles and opinion pieces about Sareum to help create further investor hunger. That is what really put NCYT and SNG on the map back in March and April. Good luck, Brighty

We should be featured in these kind of articles. Come on Sareum it's time for a PR push now.
https://www.sharebuyers.co.uk/shares/the-rise-of-covid-stocks-big-likely-winners-revealed/
Good luck, Brighty

Quite a few 500,000+ late buys have started to appear plus a 712,739 from 8.54am today. Not as chunky as earlier in the week but still good to see this level of confidence from investors on a day to day basis. Good luck all Sareum shareholders, Brighty
Oct 30 2020, 08:54 2.30 712,739 2.10 2.30 Buy £16,392.997 O

The changes announced today at Baron Oil are progressive. We need a bit of a kick start and normally a new management team provide this. We know that there is the possibility of the Dunrobin farm-in news due soon, plus we are awaiting the Timor-Leste update. Also, don't forget that the Peru and Timor ops are financed through 2020 / 2021. We have a tiny mcap of approx £3.5million today. If the next announcement is Dunrobin or perhaps a partial sale or JV of one of our other assets, that we have percentage holdings in, then the BOIL share price could multiply x 5 or even x 10 times the current price. On February 7th this year the share price went up dramatically (& that was without the concrete news we are all expecting). Good luck, Brighty

BWNG 150p+ at the start of 2020 before Covid. They have a great management team in place. There is no reason not to see that price again and probably much much higher. 3 years ago BWNG was over 300p per share. Once we know more via the RNS on November 5th the "smart money" to which you refer will no doubt be snapping up BWNG shares again. However, the real smart money has been buying BWNG for several months. When you read the investor pages you will note that great strides are also being made at paying down debt too. Check out what Next, AO, Boo and the other online retailers are saying about the permanent shift from the high street to online. This will have a big impact for N Brown also. Good luck, Brighty

TLW 38p share price back in June. I am expecting a re-rate to at least this in the short term. We started the year in the 60's and it is worth remembering that TLW was 209p per share just 12 months ago today on October 30th 2019. Lots of scope to re-rate back to at least over 100p in due course. Good luck, Brighty

Yes, top CEO. He has taken my investment in SNG at 29p to where it is today. I invest for the very long term and SNG is going to be a hold for me for quite a while yet. Good luck, Brighty

I believe that Merck's decision a few months ago to acquire the Austrian vaccine developer Themis Bioscience for its COVID-19 vaccine programme was a very very positive sign for N4P. It will be interesting to see the extent of Nigel's "Collaborations". Is it licencing deals / partnership deals or M&A? We should also be hearing soon how the partnership with Evotec is panning out and ofcourse the elephant in the room re N4P confirming that it is proceeding to full in vivo studies to demonstrate the capability of Nuvec® to generate Covid-19 specific antibodies. If this is successful the share price is going to be in the hundreds not the pennies. Good luck, Brighty

Richard Marsden really is brilliant at getting Synairgen noticed. From The Sunday Times back in March to Panorama in May through to how he is positioning Synairgen as one of the key pharmas Government's globally need to have on their speed dial. If you review what happened with Novacyt the share price gradually reversed a similar amount in %age terms after its placing. It then went up from the mid 200's up to 1200 on a raft of news. i.e. x5 following the raise. There is plenty of news coming up in the next few months to create a big re-rate. The placing was a very smart move and if you remain invested here for 12 months significant share price gains will occur in my opinion. The key investor advice I was given years ago was follow the money (£80 million placing is a huge vote of confidence) and have you got a good management team in place. The answer to both is yes. Good luck, Brighty

Interesting to note that at Bio-Europe 2020, which concluded yesterday, they’ve been focussing on the 10 programmes that have achieved global regulatory approval. As we know this includes Gilead’s Remdesivir but also more significantly for Sareum is the fact that one of the other 10 is Dexamethasone. Sareum, as I flagged up a few weeks ago, has been trialling itsTYK2 in combination with, yes you’ve guessed it, dexamethasone. The following comment from Tim Mitchell and Stephen Parker was included in their financial report a couple of years ago “The Sareum compound as a single agent was well tolerated and there was no change in tolerability when combined with dexamethasone”. It would be interesting to know if this forms part of the Covid trial because if it does Sareum has already been able to demonstrate positive results with its TYK2 and dexamethasone.

Novacyt has demonstrated what happens once revenue starts rolling in. SP today of 1050p. We will be following suit with meaningful share price gains soon enough. The presentation last night said as much. Give it a few weeks. Good luck, Brighty

£’s not pence really can happen RMM. You are so right to highlight this. I’m confident that we will see your short term 5p-6p share price for Sareum soon enough. It’s just a matter of time. The huge buying this week supports this. A great piece of work by the way re your calculations. Your musings should really help newbies realise the huge potential here with Sareum. I would add that based purely on what we have witnessed in the pharma sector with NCYT, SNG, ODX, AVCT, HEMO, N4P, YGEN, PYC, VAL etc, anything is possible and £’s not pence really can happen. Just ask those investors in Novacyt, Synairgen, Omega, and Avacta who have all seen their share prices rise from pennies to pounds. Good luck all Sareum investors, Brighty.

Huge potential here. in 6 months our share price will be x 3 or more likely x 5 of today’s share price in my opinion. Why?
• We are most likely going to have the first lateral flow antigen test in the UK
• We have multiple revenue opportunities with great margins
• £2 a test x 2.5m tests worth around £250m gross profit
• Nvct has shown that once potential revenue is factored in by the market the share price reacts accordingly. With what our ceo has had to say our revenue is going to leap exponentially and once the market takes this on board our share price will re-rate accordingly. Finncap states rivals in our sector trading at 9x earnings (& remember Finncaps new forecast should be out soon, which should create an additional re-rate in the share price)
• MHRA news due anytime
• 3rd party sales opportunities over and above UK Govt business
• 25% of all consortium contract business
All in all what’s not to like. It’s going to be a money making business from now on. Good luck, Brighty